GlassScriptPhysician profile
Cortne Benton
NPI 1255848941
$1,777.87
in general payments reported to CMS, 2019-2025
17 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $22.55 · 2024: $866 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Travel and Lodging: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.06 |
| Travel and Lodging | $495.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $631.12 | 2024 | Venaseal, Ellipsys Vascular Access System |
| Novo Nordisk INC | $251.27 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $230.68 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $124.82 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $97.32 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.17 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $71.26 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $41.19 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $40.24 | 2025 | Trelegy Ellipta |
| Ibsa Pharma INC. | $38.59 | 2024-2025 | Licart, Tirosint, Flector |
| Exact Sciences Corporation | $31.31 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $29.44 | 2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $27.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.55 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.38 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortne Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.